Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | EML4 - RET |
Therapy | RXDX-105 + Trametinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - RET | lung adenocarcinoma | no benefit | RXDX-105 + Trametinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, the addition of Mekinist (trametinib) did not increase sensitivity to Agerafenib (RXDX-105) treatment in a patient-derived lung adenocarcinoma cell line harboring EML4-RET in culture (PMID: 33795352). | 33795352 |
PubMed Id | Reference Title | Details |
---|---|---|
(33795352) | Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to RET inhibitors and differential regulation of downstream signaling. | Full reference... |